BHB-1893 vs. Placebo for Symptomatic Non-obstructive Hypertrophic Cardiomyopathy

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 600 participants.

Also called NCT07946107

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 600 participants (planned count) (from the registry)
Sponsor
Braveheart Bio, Inc. (from the registry)
Registry
  • NCT NCT07946107
  • EU CT 2026-527471-29-00
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07946107. Randomized; quadruple masking; primary purpose treatment. Start 2026-12 (anticipated); primary completion 2029-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
BHB-1893 vs. Placebo for Symptomatic Non-obstructive Hypertrophic Cardiomyopathy
Acronym
NOBLEHEART-HCM
Condition
Cardiomyopathy, Hypertrophic Non-Obstructive
Intervention (Drug)
BHB-1893
Intervention (Other)
Placebo
Lead sponsor
Braveheart Bio, Inc. (class: industry)

Record details

Record id
cardio:ct-nct07946107
Content hash
7bc647fdfd48e9063b81c5f514f83e74c0be2a5ff793cf9754781599dd161043